| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/06/2005 | WO2005000302A1 Use of pyrazolopyridines for the treatment of cognitive deficits |
| 01/06/2005 | WO2005000300A1 Substituted 5-membered ring compounds and their use |
| 01/06/2005 | WO2005000295A1 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| 01/06/2005 | WO2005000290A1 Ibuprofen-containing film-coated tablet |
| 01/06/2005 | WO2005000288A2 Treatment of protein aggregation disorders |
| 01/06/2005 | WO2005000205A2 Methods and compositions for modulating serum cortisol levels |
| 01/06/2005 | WO2005000203A2 Methods for treating cognitive impairment and improving cognition |
| 01/06/2005 | WO2004096845A3 Beta-amyloid inhibitors and use thereof |
| 01/06/2005 | WO2004087646A3 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
| 01/06/2005 | WO2004082574A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d5 (drd5) |
| 01/06/2005 | WO2004073595A3 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use |
| 01/06/2005 | WO2004073588A3 Diagnostics and therapeutics for diseases associated with g protein coupled receptor r35 (r35) |
| 01/06/2005 | WO2004071392A3 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) |
| 01/06/2005 | WO2004071380A3 Drugs containing substituted 2-aryl-aminoacetic acid compounds |
| 01/06/2005 | WO2004071378A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 01/06/2005 | WO2003103643A8 Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor |
| 01/06/2005 | WO2003042177A8 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 01/06/2005 | WO2003032912A9 Treatment of cns disorders using cns target modulators |
| 01/06/2005 | US20050004381 Therapy for headaches; analgesics; nausea; anxiolytic agents; anticonvulsants; central nervous system disorders |
| 01/06/2005 | US20050004363 4-oxoimidazolidine-2-spiropiperidine derivatives |
| 01/06/2005 | US20050004360 Compounds and methods for modulation of estrogen receptors |
| 01/06/2005 | US20050004352 Single-chain multiple antigen-binding molecule, its preparation and use |
| 01/06/2005 | US20050004348 Sodium transport protein for use as tool in identifying modulator for treatment of hyperphosphatemia or hypophosphatemia |
| 01/06/2005 | US20050004207 Substituted isoindoles and the use thereof |
| 01/06/2005 | US20050004204 2-Iminopyrrolidine derivatives |
| 01/06/2005 | US20050004202 Such as 3-[1-(3-methoxypropyl )-1H-indazol-3-yl]-4-[1-(3-pyridinyl )-1H-indol-3-yl]-1H-pyrrole-2,5-dione; protein kinase C and/or glycogen synthase kinase-3 diseases |
| 01/06/2005 | US20050004201 Cardiovascular and inflammatory diseases; immunological, dermatological, oncological and central nervous system disorders; diabetes and associated disorders; protein kinase C and glycogen synthase kinase-3 |
| 01/06/2005 | US20050004197 Thrombin receptors antagonists; oral efficacy |
| 01/06/2005 | US20050004180 Conditions mediated by beta chemokine receptor 2, monocyte chemotactic protein 1 and/or their interaction; such as 4-acetyl-5-cyclohexyl-3-amino-1-(4-methylphenyl)-1,5-dihydro-2H-pyrrol-2-one |
| 01/06/2005 | US20050004168 New substituted pyridine or piperidine compounds |
| 01/06/2005 | US20050004167 Such as dibenzofuran-2-carboxylic acid 2-(phenylsulfonyl)hydrazide |
| 01/06/2005 | US20050004157 Serotonin uptake inhibitors and 5-HT1A receptor antagonists; antidepressants; psychological disorders |
| 01/06/2005 | US20050004154 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders |
| 01/06/2005 | US20050004153 inhibitors of Lymphocyte Function-associated Antigen 1 (LFA-1)/intercellular adhesion molecule (ICAM); use treating transplant rejection, rheumatoid arthritis, diabetes, inflammatory bowel disease, and chronic obstructive pulmonary disease; 2,4-dioxo-1,3,7-triazaspiro[4.4]nonanes |
| 01/06/2005 | US20050004149 Pyrimidine compound and medicinal composition thereof |
| 01/06/2005 | US20050004142 furo(2,3-d)pyrimidine and thieno(2,3-d)pyrimidine compounds for treating cancer and hyperproliferative diseases; receptor tyrosine kinase inhibitors |
| 01/06/2005 | US20050004138 Overcoming phobias |
| 01/06/2005 | US20050004137 Utilizing ziprasidone, derivative or related compound |
| 01/06/2005 | US20050004136 Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful as neurokinin receptor modulators |
| 01/06/2005 | US20050004135 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 01/06/2005 | US20050004134 Adenosine antagonists; having 6-oxo-1,6-dihydro-3-pynidazinyl functionality; synthesis |
| 01/06/2005 | US20050004133 Inhibiting ligand gated ion channel vanilloid receptor (VR1); pain relievers; such as 6-(3,4-dichloro-phenyl)-N-(2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-nicotinamide |
| 01/06/2005 | US20050004132 Pain, immune diseases, inflammatory disorders; low toxicity; such as 1-[2-(3-(4-Pyridyl)phenyl)ethyl]-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 1-oxide |
| 01/06/2005 | US20050004130 New metabotropic glutamate receptor compounds |
| 01/06/2005 | US20050004128 4-(6-chloro-, methyl- or thien-3-yl-oxazolo[4,5-b]pyrid-2-yl)-1,4-diazabicyclo[3.2.2]nonane or salts; nicotinic receptor associated disorders; cholinergic agents |
| 01/06/2005 | US20050004125 Such as 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile; bipolar disorder, pain, type 2 diabetes |
| 01/06/2005 | US20050004120 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 01/06/2005 | US20050004119 Trypsin like serine protease enzyme inhibitors |
| 01/06/2005 | US20050004115 such as 4-(4-(2-Fluorobenzyloxy)phenyl)-4-oxobutyric acid; for treatment of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis |
| 01/06/2005 | US20050004110 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 01/06/2005 | US20050004106 Therapy for drug resistant disease; anxiolytic agents; psychological disorders |
| 01/06/2005 | US20050004105 Using serotonine receptor antagonist |
| 01/06/2005 | US20050004102 Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain |
| 01/06/2005 | US20050004101 Therapy for schizophrenia, obsessive complusive disorders; antidepressants; anxiolytic agents; panic disorders; antiepileptic agents; analgesics; headaches; sleep disorders; eating disorders |
| 01/06/2005 | US20050004099 Spiroazabicyclic heterocyclic compounds |
| 01/06/2005 | US20050004096 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 01/06/2005 | US20050004083 such as 3-(aminocyclopentanyl)butylphosphinic acid ; GABA (gamma-amino-butyric acid) receptor agonists/antagonists; for memory enhancement |
| 01/06/2005 | US20050004082 Ether compounds |
| 01/06/2005 | US20050004079 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
| 01/06/2005 | US20050004039 Selective analgesic agents |
| 01/06/2005 | US20050004035 Antiinflammatory agents; multiple sclerosis; inflamamtory bowel disorders; antitumor agents; sepsis |
| 01/06/2005 | US20050004025 Modulation of acetylcholine receptors; central nervous system disorders; schizophenia; skin disorders; Alzheimer's and Parkinson's disease |
| 01/06/2005 | US20050004019 Neuroprotective peptides and uses thereof |
| 01/06/2005 | US20050004016 Quantitative analysis of amino acid sequences; genetic engineering |
| 01/06/2005 | US20050004015 Novel haemopoietin receptor and genetic sequences encoding same |
| 01/06/2005 | US20050003976 Mixture of vegetable oils, aromatic solvent and caffeine; nerve stimulant perfume; topical applying |
| 01/06/2005 | US20050003531 Isolating and generating postmitotic neurons from embryonic spinal cord tissue that are capable of multiple neuronal phenotypes for use in treatment and prevention of nervous system disorders |
| 01/06/2005 | US20050003481 Novel glutamic acid receptor and utilization thereof |
| 01/06/2005 | US20050003453 G-CSF analog compositions and methods |
| 01/06/2005 | US20050003370 Expression vector comprising nucleotide sequences coding membrane receptor proteins for use in identifying modulators for treatment and prevention of cell proliferative, nervous system, reproductive cardiovascular and inflammation disorders |
| 01/06/2005 | US20050003353 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/06/2005 | US20050003352 Comprises recombinant mitochondrial transport protein for diagnosis, prevention and treatment of alzheimer's, diabetes, parkinson's, huntington's, cancers |
| 01/06/2005 | US20050003018 Removing amyloid deposits from brain without detrimental side effects; combining with such as clioquinol and vitamin B12; kits |
| 01/06/2005 | US20050003002 Tramadol hydrochloride with such as diclofenac sodium; reduced water solubility |
| 01/06/2005 | US20050002985 Device with recessed tracks for forming a cellular network |
| 01/06/2005 | US20050002950 Vaccine preventing infection |
| 01/06/2005 | US20050002937 Anti-IL-12 antibodies, compositions, methods and uses |
| 01/06/2005 | CA2556706A1 Treatment of amyloid- and epileptogenesis-associated diseases |
| 01/06/2005 | CA2531020A1 Cannabinoid receptor modulator |
| 01/06/2005 | CA2530662A1 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 01/06/2005 | CA2530649A1 Antiepileptic agent |
| 01/06/2005 | CA2530381A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic or antidepressant agent, and use thereof for the preparationof a medicament that prevents the adverse effects of psychotropic drugs |
| 01/06/2005 | CA2529353A1 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
| 01/06/2005 | CA2529227A1 Benzodiazepine cgrp receptor antagonists |
| 01/06/2005 | CA2529083A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | CA2528627A1 Treatment of protein aggregation disorders |
| 01/06/2005 | CA2528619A1 Diphenylpyridine derivatives, preparation and therapeutic application thereof |
| 01/06/2005 | CA2528347A1 Orally bioavailable low molecular weight metalloporphyrins as antioxidants |
| 01/06/2005 | CA2527689A1 Recombinant anti-cd30 antibodies and uses thereof |
| 01/06/2005 | CA2527284A1 Methods and compositions for modulating serum cortisol levels |
| 01/06/2005 | CA2526487A1 Heterocyclic methyl sulfone derivative |
| 01/06/2005 | CA2522275A1 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| 01/05/2005 | EP1493745A1 New crystalline and amorphous form of a triazolo(4,5-D)pyrimidine compound |
| 01/05/2005 | EP1493744A1 Tropane analogs and methods for inhibition of monoamine transport |
| 01/05/2005 | EP1493743A1 Substituted bipiperidine intermediates and derivatives thereof |
| 01/05/2005 | EP1493742A1 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| 01/05/2005 | EP1493732A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 01/05/2005 | EP1493442A1 Reboxetine for treating peripheral neuropathy |
| 01/05/2005 | EP1493438A1 Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| 01/05/2005 | EP1493034A2 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |